A Series C funding round has brought in $20 million for Vaxart, a San Francisco-based developer of oral flu vaccines. Vaxart is developing vaccines for H1N1 seasonal influenza, H5N1 avian influenza and H7N9 avian influenza.
Advanced Liquid Logic has received financing from Square 1 Bank to advance the development of its microfluidics technology for the processing of very small amounts of liquid samples, including blood. GenMark Diagnostics has licensed the company's lab-on-a-chip technology for use in developing advanced tests.
Japanese researchers were able to capture a detailed image of the structure of an enzyme that influenza viruses need to reproduce. The finding could lead to the development of novel drugs that target such viruses, including the H5N1 bird flu virus, one of the researchers said.
Another influenza virus -- not necessarily the H5N1 bird flu virus -- could mutate into a global pandemic, U.S. health experts warned. Little is known about the exact mutation of viruses, and it would be a mistake to focus on only one suspect, said Anthony Fauci, head of the U.S. National Institute of Allergy and Infectious Diseases.